CLINICAL STUDIES
Chimeric 7e3 Fab (ReoPro) decreases detectable CD11b on neutrophils from patients undergoing coronary angioplasty
Judith K. Mickelson, MD, FACC*  ,
M. Nadir Ali, MD* ,
Neal S. Kleiman, MD, FACC*,
Nasser M. Lakkis, MD*,
Thomas W. Chow, PhD ,
Bonnie J. Hughes, BS and
C. Wayne Smith, MD
* Section of Cardiology, Department of Medicine, Baylor College of Medicine, Houston, Texas 77030 USA
Speros P. Martel Laboratory of Leukocyte Biology, Department of Pediatrics, Baylor College of Medicine; Houston, Texas 77030 USA
Veterans Administration Medical Center, Houston, Texas, 77030 USA
Rice University, Houston, Texas, 77030, USA
Manuscript received June 3, 1998;
revised manuscript received August 4, 1998,
accepted September 4, 1998.
Address for correspondence: C. Wayne Smith, Room 6014, Children’s Nutrition Research Center, 1100 Bates, Houston, Texas 77030-2600
Objectives. The purpose of this study was to monitor the effects of chimeric 7E3 Fab (ReoPro) on leukocyte and platelet activation and interaction during coronary angioplasty.
Background. Increased expression of CD11b on monocytes and neutrophils promotes their adhesion to endothelial cells, extracellular matrix and smooth muscle cells. Thrombin-activated platelets adhere via P-selectin to monocytes and neutrophils. These cell interactions may affect the outcome of coronary angioplasty.
Methods. During coronary angioplasty, venous blood was obtained for flow cytometric detection of leukocyte CD11b; platelet CD41a, CD61a and CD62P; the percentage of leukocytes with adherent platelets and the intensity of bound platelet fluorescence.
Results. Leukocyte CD11b expression increased after angioplasty in control patients (neutrophils 171 ± 25 to 255 ± 31 mean fluorescence intensity [MFI, mean ± SEM], n = 25, p < 0.0001; monocytes 200 ± 40 to 248 ± 36 MFI, n = 17, p < 0.05) and decreased in the patients selected to receive chimeric 7E3 Fab (neutrophils 146 ± 30 to 82 ± 22 MFI, n = 25, p < 0.0001; monocytes 256 ± 53 to 160 ± 38 MFI, n = 17, p < 0.05). Neutrophil CD11b decreased after in vitro incubation of whole blood with chimeric 7E3 Fab (n = 5, p = 0.01), but fMLP-induced increases in CD11b were not prevented. The CD11b expression was unchanged and increased with fMLP stimulation after in vitro incubation of isolated neutrophils with chimeric 7E3 Fab. Direct-labeled chimeric 7E3 Fab was not detected bound to neutrophils in whole blood or isolated cells using flow cytometric techniques. Adhesion of isolated neutrophils to protein-coated glass was not prevented by in vitro incubation with chimeric 7E3 Fab. Platelet activation increased after angioplasty in control patients (CD62P 8.9 ± 0.8 to 12.3 ± 1.2 MFI, n = 25, p < 0.05; CD41a 382 ± 25 to 454 ± 26 MFI, n = 25, p < 0.05, CD61a 436 ± 52 to 529 ± 58 MFI, n = 11, p < 0.05); it did not increase in the patients selected to receive chimeric 7E3 Fab (CD62P 13.2 ± 1.0 to 9.0 ± 0.9 MFI, n = 25, p < 0.05; CD61a 398 ± 32 to 410 ± 38 MFI, n = 7, p = NS). Leukocytes with adherent platelets tended to increase in the control group of patients and decrease after the procedure in patients selected to receive chimeric 7E3 Fab; individual and procedure-related variability were marked.
Conclusions. Despite standard aspirin and heparin therapy, leukocyte and platelet activation with platelet adherence to leukocytes occurs after coronary angioplasty. Although chimeric 7E3 Fab does not bind to leukocytes directly, it influences CD11b expression in whole blood. Modulation of platelet and leukocyte activation and interaction by chimeric 7E3 Fab may contribute to an improved outcome after coronary angioplasty.
This article has been cited by other articles:
|
|
|
|
 
S.-H. Lee, J. E. Prince, M. Rais, F. Kheradmand, C. M. Ballantyne, G. Weitz-Schmidt, C. W. Smith, and D. B. Corry
Developmental Control of Integrin Expression Regulates Th2 Effector Homing
J. Immunol.,
April 1, 2008;
180(7):
4656 - 4667.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. E Asberg and V. Videm
Concentration-dependent effect of abciximab on platelets and neutrophils in a model of cardiopulmonary bypass
Perfusion,
November 1, 2006;
21(6):
343 - 352.
[Abstract]
[PDF]
|
|
|
|
|
|
|
W. Kim, M. H. Jeong, K. H. Kim, I. S. Sohn, Y. J. Hong, H. W. Park, J. H. Kim, Y. K. Ahn, J. G. Cho, J. C. Park, et al.
The Clinical Results of a Platelet Glycoprotein IIb/IIIa Receptor Blocker (Abciximab: ReoPro)-Coated Stent in Acute Myocardial Infarction
J. Am. Coll. Cardiol.,
March 7, 2006;
47(5):
933 - 938.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. S. Kleiman
Platelets, the cardiologist, and coronary artery disease: moving beyond aggregation
J. Am. Coll. Cardiol.,
June 2, 2004;
43(11):
1989 - 1991.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. T Dirksen, G. Laarman, A. W.J van 't Hof, G. Guagliumi, W. A.L Tonino, L. Tavazzi, D. J.G.M Duncker, M. L Simoons, and on behalf of the PARI-MI Investigators
The effect of ITF-1697 on reperfusion in patients undergoing primary angioplasty: Safety and efficacy of a novel tetrapeptide, ITF-1697
Eur. Heart J.,
March 1, 2004;
25(5):
392 - 400.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. J. Kereiakes
Adjunctive Pharmacotherapy before Percutaneous Coronary Intervention in Non-ST-Elevation Acute Coronary Syndromes: The Role of Modulating Inflammation
Circulation,
October 21, 2003;
108(90161):
III-22 - 27.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Kupatt, R. Wichels, J. Horstkotte, F. Krombach, H. Habazettl, and P. Boekstegers
Molecular mechanisms of platelet-mediated leukocyte recruitment during myocardial reperfusion
J. Leukoc. Biol.,
September 1, 2002;
72(3):
455 - 461.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. D. Aymong, M. J. Curtis, M. Youssef, M. M. Graham, L. Shewchuk, W. Leschuk, and T. J. Anderson
Abciximab Attenuates Coronary Microvascular Endothelial Dysfunction After Coronary Stenting
Circulation,
June 25, 2002;
105(25):
2981 - 2985.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. W. Baran, M. Nguyen, G. R. McKendall, C. T. Lambrew, G. Dykstra, S. T. Palmeri, R. J. Gibbons, S. Borzak, B. E. Sobel, S. G. Gourlay, et al.
Double-Blind, Randomized Trial of an Anti-CD18 Antibody in Conjunction With Recombinant Tissue Plasminogen Activator for Acute Myocardial Infarction: Limitation of Myocardial Infarction Following Thrombolysis in Acute Myocardial Infarction (LIMIT AMI) Study
Circulation,
December 4, 2001;
104(23):
2778 - 2783.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. J. Topol, D. J. Moliterno, H. C. Herrmann, E. R. Powers, C. L. Grines, D. J. Cohen, E. A. Cohen, M. Bertrand, F.-J. Neumann, G. W. Stone, et al.
Comparison of Two Platelet Glycoprotein IIb/IIIa Inhibitors, Tirofiban and Abciximab, for the Prevention of Ischemic Events with Percutaneous Coronary Revascularization
N. Engl. J. Med.,
June 21, 2001;
344(25):
1888 - 1894.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Kupatt, H. Habazettl, P. Hanusch, R. Wichels, D. Hahnel, B. F. Becker, and P. Boekstegers
c7E3Fab Reduces Postischemic Leukocyte-Thrombocyte Interaction Mediated by Fibrinogen : Implications for Myocardial Reperfusion Injury
Arterioscler Thromb Vasc Biol,
October 1, 2000;
20(10):
2226 - 2232.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Chandrasekar and J.-F. Tanguay
Platelets and restenosis
J. Am. Coll. Cardiol.,
March 1, 2000;
35(3):
555 - 562.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. J Schneider, D. J Taatjes, and B. E Sobel
Paradoxical inhibition of fibrinogen binding and potentiation of {alpha}-granule release by specific types of inhibitors of glycoprotein IIb-IIIa
Cardiovasc Res,
January 14, 2000;
45(2):
437 - 446.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. A. Waldmann, R. Levy, and B. S. Coller
Emerging Therapies: Spectrum of Applications of Monoclonal Antibody Therapy
Hematology,
January 1, 2000;
2000(1):
394 - 408.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
